• Explore /
  • Poster
  • / CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.

CheckMate 648: A randomized phase 3 study of nivolumab plus ipilimumab or nivolumab combined with fluorouracil plus cisplatin versus fluorouracil plus cisplatin in patients with unresectable advanced, recurrent, or metastatic previously untreated esophageal squamous cell carcinoma.

Abstract Poster

Authors

null

Jaffer A. Ajani

University of Texas MD Anderson Cancer Center, Houston, TX

Jaffer A. Ajani , Ken Kato , Yuichiro Doki , Ian Chau , Ioannis Xynos , Agnes Balogh , Yuko Kitagawa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT03143153

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr TPS193)

DOI

10.1200/JCO.2018.36.4_suppl.TPS193

Abstract #

TPS193

Poster Bd #

M7

Abstract Disclosures

Similar Posters

First Author: John A. Bridgewater

First Author: Yelena Yuriy Janjigian

First Author: Inge Marie Svane

First Author: Jin Li